OS Fund

Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that focuses on the development and manufacture of enzymes and specialty chemical products. Established in 2008, Arzeda employs intelligent protein design technology, integrating physics-based methodologies with artificial intelligence to create innovative designer proteins and enzymes. Its product portfolio caters to various industries, including polymers, pharmaceuticals, and industrial chemicals, enabling clients to access high-performance solutions that also emphasize cost-effectiveness and sustainability.

Kenota Health is a company that specializes in the development of advanced diagnostic tools for allergy testing in humans. Their innovative point-of-care system streamlines the allergy testing process by utilizing a small blood sample, which is analyzed through their equipment to detect allergen sensitization within minutes. This non-invasive technology not only simplifies the testing procedure but also provides timely results directly to healthcare providers, enhancing the overall quality of diagnostic information available to physicians. By offering a safer and more cost-effective alternative to traditional allergy testing methods, Kenota Health aims to improve patient outcomes and facilitate better healthcare decision-making.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

GRO Biosciences is a biotechnology company focused on developing advanced protein therapeutics to address various health conditions, including diabetes, growth disorders, and autoimmunity. The company employs innovative technologies in computational protein design and synthetic biology, which enable it to create genomically recoded strains of bacteria capable of incorporating non-standard amino acids into proteins. This approach enhances the properties of the proteins, resulting in increased potency, stability, and targeted delivery. Through its technology platform, GRO Biosciences aims to provide improved treatment options across multiple disease classes, contributing to advancements in medical therapeutics.

uBiome, Inc. was a microbial genomics company based in San Francisco, California, founded in 2012. It specialized in sequencing-based clinical microbiome tests, offering products such as SmartGut, a test for identifying pathogenic and commensal microorganisms related to infections, and SmartJane, a women's health screening test that detects various conditions including HPV and STIs. The company also provided Explorer kits for citizen scientists and researchers, as well as SmartFlu, a clinical respiratory test. By leveraging precision sequencing combined with machine learning and artificial intelligence, uBiome aimed to enhance the understanding of the human microbiome, enabling healthcare providers to deliver more accurate diagnoses and empowering patients to manage their health more effectively. However, uBiome faced financial difficulties and filed for Chapter 11 bankruptcy in September 2019, which was later converted to Chapter 7 on October 11, 2019.

Verge Genomics is a biotechnology company focused on transforming drug discovery through the application of artificial intelligence. Founded by experts in machine learning and seasoned neuroscience drug developers, the company aims to leverage advancements in computational genomics and insights into neuroscience to discover innovative therapeutics for neurodegenerative diseases. Its drug discovery platform employs machine learning algorithms to analyze large datasets, identifying potential drug targets and predicting effective treatments. By accelerating the development of life-saving therapies, Verge Genomics seeks to enhance patient outcomes and reduce the costs associated with pharmaceutical development, thereby addressing critical challenges in the healthcare sector.

Lygos is a biotechnology company based in Berkeley, California, established in 2011. It focuses on developing sustainable specialty chemicals by engineering microbes to convert sugars into high-value industrial chemicals. The company targets compounds where biological production offers a cost advantage over traditional petrochemical methods. Lygos employs advanced throughput screening and strain construction techniques to optimize pathways for converting inexpensive, renewable feedstock into valuable chemicals. By replacing persistent and potentially toxic chemicals with cleaner, cost-effective alternatives, Lygos aims to provide high-performing, sustainable solutions for business-to-business customers across various industries.

Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

NuMat Technologies, Inc. is a technology company based in Skokie, Illinois, specializing in the design and integration of atomically engineered materials for gas delivery, separation, and purification systems. Utilizing metal-organic frameworks (MOFs), which are nanoporous materials that can selectively interact with targeted gases and chemicals, NuMat develops advanced solutions like ION-X for the sub-atmospheric storage and delivery of hazardous implant gases. The company aims to revolutionize precision engineering by creating molecularly programmed systems that enhance resource creation and utilization. Its comprehensive platform combines material discovery software with rapid prototyping and system integration, catering to clients in sectors such as chemicals, industrials, electronics, and life sciences, thereby enabling them to meet their innovation and sustainability goals. Founded in 2012, NuMat Technologies is committed to unlocking new performance levels and production economics in its field.

Aria Pharmaceuticals is a preclinical-stage pharmaceutical company focused on discovering and developing novel small molecule therapies for complex and hard-to-treat diseases. Utilizing an artificial intelligence-driven drug discovery platform, Aria aims to redefine traditional drug development processes, significantly reducing the time required for discovery and increasing success rates by up to 30 times. The company builds its own pipeline of therapeutic candidates while also collaborating with biotechnology and pharmaceutical companies to identify and develop new drug candidates. Aria's innovative approach allows it to address a wide array of therapeutic areas and aims to provide breakthrough treatments for over 1,000 diseases. Founded in 2014 and based in Mountain View, California, Aria Pharmaceuticals is committed to advancing healthcare solutions for patients in urgent need.

GRO Biosciences is a biotechnology company focused on developing advanced protein therapeutics to address various health conditions, including diabetes, growth disorders, and autoimmunity. The company employs innovative technologies in computational protein design and synthetic biology, which enable it to create genomically recoded strains of bacteria capable of incorporating non-standard amino acids into proteins. This approach enhances the properties of the proteins, resulting in increased potency, stability, and targeted delivery. Through its technology platform, GRO Biosciences aims to provide improved treatment options across multiple disease classes, contributing to advancements in medical therapeutics.

3T Biosciences, Inc. is an immunotherapy company founded in 2017 and headquartered in Menlo Park, California. The company focuses on developing innovative drugs and medical research facilities aimed at offering cures for cancer-related diseases. By leveraging synthetic biology and machine learning, 3T Biosciences seeks to discover novel targets for treating cancer and other T-cell-mediated diseases, thereby enhancing treatment options available to healthcare providers and improving patient outcomes.

Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that focuses on the development and manufacture of enzymes and specialty chemical products. Established in 2008, Arzeda employs intelligent protein design technology, integrating physics-based methodologies with artificial intelligence to create innovative designer proteins and enzymes. Its product portfolio caters to various industries, including polymers, pharmaceuticals, and industrial chemicals, enabling clients to access high-performance solutions that also emphasize cost-effectiveness and sustainability.

Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

Synthego Corporation is a genome engineering company that specializes in accelerating life science research and development to enhance human health. Established in 2012 and headquartered in Redwood City, California, Synthego utilizes an innovative platform that integrates hardware, software, bioinformatics, chemistries, and molecular biology. This full-stack approach provides researchers with tools for gene editing, including engineered cells, CRISPR kits, and bioinformatics for guide RNA optimization and analysis. The products support various applications in basic research, therapeutic development, disease modeling, and diagnostics. Synthego serves a diverse range of customers, including biotechnology firms, universities, and therapeutic developers worldwide, distributing its offerings online and through partners in multiple countries. By leveraging automation and machine learning, Synthego enables genetic engineers and medical professionals to conduct research that is both rapid and cost-effective.

Lygos is a biotechnology company based in Berkeley, California, established in 2011. It focuses on developing sustainable specialty chemicals by engineering microbes to convert sugars into high-value industrial chemicals. The company targets compounds where biological production offers a cost advantage over traditional petrochemical methods. Lygos employs advanced throughput screening and strain construction techniques to optimize pathways for converting inexpensive, renewable feedstock into valuable chemicals. By replacing persistent and potentially toxic chemicals with cleaner, cost-effective alternatives, Lygos aims to provide high-performing, sustainable solutions for business-to-business customers across various industries.

Prospect Bio is a synthetic biology company based in Brisbane, California, that specializes in developing biosensors for the detection of small molecules. These biosensors utilize living cells to perform complex chemical measurements, offering a cost-effective and scalable alternative to traditional testing methods that often rely on expensive and slow laboratory equipment. By addressing the need for improved testing solutions driven by regulatory demands, quality control, and supply chain concerns, Prospect Bio aims to transform testing processes across various industries. The company collaborates with a diverse array of partners, including major players in the wine industry, agriculture, prenatal diagnostics, and biotechnology. Its innovative approach combines microbial biotechnologies with automation and computational tools, enabling rapid biosensor and pathway discovery for medical research and other applications.

Emulate, Inc. is a biotechnology company specializing in organs-on-chips technology that emulates human biology to enhance the understanding of diseases, medicines, chemicals, and food impacts on human health. The company develops organ-chips that replicate normal organ functions as well as various disease states, primarily targeting the lung, intestine, liver, and skin. Emulate's innovative human emulation system provides researchers with advanced in vitro models that offer more precise and detailed predictions of human responses compared to traditional experimental methods, such as cell culture or animal testing. The company serves a diverse range of markets, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic research. Founded in 2013 and based in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. before rebranding in July 2014.

MetaMixis Inc. specializes in the development of enzymes and metabolic pathways for microorganisms that produce chemicals. Founded in 2012 and headquartered in Vancouver, Canada, the company leverages its expertise in synthetic biology, environmental genomics, and bioinformatics to revolutionize enzyme and pathway discovery. MetaMixis creates biosensors that utilize an environment's inherent capabilities to detect biochemical transformations. Additionally, it screens diverse environmental DNA libraries to generate a multi-candidate portfolio of enzymes and pathways designed for specific target transformations. The company aims to contribute to the bioeconomy by advancing innovative solutions in biochemistry and sustainability.

Kenota Health is a company that specializes in the development of advanced diagnostic tools for allergy testing in humans. Their innovative point-of-care system streamlines the allergy testing process by utilizing a small blood sample, which is analyzed through their equipment to detect allergen sensitization within minutes. This non-invasive technology not only simplifies the testing procedure but also provides timely results directly to healthcare providers, enhancing the overall quality of diagnostic information available to physicians. By offering a safer and more cost-effective alternative to traditional allergy testing methods, Kenota Health aims to improve patient outcomes and facilitate better healthcare decision-making.

Kenota Health is a company that specializes in the development of advanced diagnostic tools for allergy testing in humans. Their innovative point-of-care system streamlines the allergy testing process by utilizing a small blood sample, which is analyzed through their equipment to detect allergen sensitization within minutes. This non-invasive technology not only simplifies the testing procedure but also provides timely results directly to healthcare providers, enhancing the overall quality of diagnostic information available to physicians. By offering a safer and more cost-effective alternative to traditional allergy testing methods, Kenota Health aims to improve patient outcomes and facilitate better healthcare decision-making.

NuMat Technologies, Inc. is a technology company based in Skokie, Illinois, specializing in the design and integration of atomically engineered materials for gas delivery, separation, and purification systems. Utilizing metal-organic frameworks (MOFs), which are nanoporous materials that can selectively interact with targeted gases and chemicals, NuMat develops advanced solutions like ION-X for the sub-atmospheric storage and delivery of hazardous implant gases. The company aims to revolutionize precision engineering by creating molecularly programmed systems that enhance resource creation and utilization. Its comprehensive platform combines material discovery software with rapid prototyping and system integration, catering to clients in sectors such as chemicals, industrials, electronics, and life sciences, thereby enabling them to meet their innovation and sustainability goals. Founded in 2012, NuMat Technologies is committed to unlocking new performance levels and production economics in its field.

Mozio, Inc. is an online airport transportation search and booking engine based in San Francisco, California, founded in 2012. The company's platform enables travelers to easily search and book a variety of transportation options, including shared ride shuttles, private vans, taxis, limousines, and SUVs, across multiple regions, including the United States, Canada, Latin America, Europe, and Asia. Designed to simplify the travel experience, Mozio aggregates local transportation services, helping users navigate their options and secure the best deals for their airport transfers. Additionally, Mozio offers API and affiliate programs, allowing travel websites and agents to sell various transportation services, thereby enhancing customer loyalty and monetization opportunities for travel brands.

3Scan, Inc. is a technology company based in San Francisco, California, that specializes in the development of advanced microscopy tools and software for tissue analysis. Founded in 2011, the company focuses on automating the processes of tissue sectioning and imaging through its innovative knife-edge scanning microscopes. By integrating automation, machine learning, and computer vision, 3Scan enables researchers and medical professionals to extract spatial data from tissue samples, facilitating detailed 3D visualizations and comprehensive quantitative analysis of complex anatomical structures. This approach enhances the throughput and accuracy of tissue analysis compared to traditional histopathology, ultimately advancing the understanding of diseases that manifest at the tissue level, such as cancer, Alzheimer's, and other neurodegenerative disorders. 3Scan's technology aims to drive the discovery of new diagnostics and therapeutics in the field of biomedical research.

Elysium Health, Inc., established in 2014 and headquartered in New York, specializes in the development and sale of health supplements. The company focuses on two primary areas: cellular health and optimization, and long-term brain health. It offers a proprietary formulation of natural compounds, designed to support overall well-being at the cellular level, which is sold directly to consumers via its online platform. Additionally, Elysium provides a biological age testing solution.

Planetary Resources specializes in asteroid mining services aimed at facilitating commercial deep space exploration. The company focuses on identifying and extracting raw materials, particularly water and precious metals, from asteroids. By harnessing these resources, Planetary Resources aims to support the development of a space economy, where water can be converted into rocket fuel and consumable supplies for human habitation beyond Earth. This approach is intended to play a crucial role in enabling humanity to evolve into a multi-planetary species, utilizing the wealth of resources available in space to fuel long-term expansion and exploration.

Nanoly Bioscience, Inc. is a biotechnology company that specializes in developing polymers designed to stabilize temperature-sensitive molecules, such as vaccines and therapeutics, during storage and transportation. Founded in 2012 and headquartered in Denver, Colorado, Nanoly's innovative polymer technology allows these sensitive products to survive without refrigeration, thereby extending their shelf life and eliminating the need for temperature-controlled storage in certain cases. This advancement is particularly significant for the distribution of vaccines and protein-based therapeutics, offering a practical solution to the challenges posed by conventional cold chain logistics.

Human Longevity (HLI) is a genomic-based health intelligence company focused on proactive healthcare and enhancing quality of life. Founded in 2013 and headquartered in San Diego, California, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with advanced machine learning techniques, to drive medical discoveries and transform healthcare practices. The company operates multiple business areas, including the HLI Health Nucleus, a clinical research center that employs whole-genome sequencing, advanced imaging, and curated personal health data to provide an in-depth understanding of individual health. HLI's platform also addresses age-related decline in stem cell function and focuses on major health issues such as cancer, diabetes, obesity, heart and liver diseases, and dementia. By integrating DNA sequencing with expert analysis, HLI aims to empower individuals to take control of their health and shift medical care from a reactive to a proactive approach.

Emulate, Inc. is a biotechnology company specializing in organs-on-chips technology that emulates human biology to enhance the understanding of diseases, medicines, chemicals, and food impacts on human health. The company develops organ-chips that replicate normal organ functions as well as various disease states, primarily targeting the lung, intestine, liver, and skin. Emulate's innovative human emulation system provides researchers with advanced in vitro models that offer more precise and detailed predictions of human responses compared to traditional experimental methods, such as cell culture or animal testing. The company serves a diverse range of markets, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic research. Founded in 2013 and based in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. before rebranding in July 2014.

Pivot Bio, Inc. is a biotechnology company founded in 2010 and based in Emeryville, California. The company focuses on enhancing crop nutrition through a deep understanding of the microbiome, utilizing engineered microbes to deliver essential nutrients, protect against pests, and improve crop quality. By leveraging data science and engineering principles, Pivot Bio aims to map the dynamics of the plant microbiome and develop beneficial traits. Their proprietary ON Technology utilizes naturally occurring microbes to supply nitrogen to crops, offering a sustainable alternative to synthetic fertilizers. This innovation not only helps farmers increase yields but also contributes to reducing reliance on petrochemical fertilizers, ultimately promoting healthier ecosystems and cleaner air and water. Pivot Bio's current initiatives primarily focus on enabling microbes to fix and supply nitrogen for corn, addressing the growing need for sustainable agricultural practices as the global population expands.

Viv Labs, Inc., established in 2012 and headquartered in San Jose, California, specializes in developing an artificial intelligence platform that facilitates interaction between users and various devices, services, and platforms through an intelligent, conversational interface. The company, formerly known as Six Five Labs, operates as a subsidiary of Samsung Research America since October 7, 2016. Viv Labs enables developers to distribute their products globally via this intuitive interface, which learns and improves daily based on user interactions.

Verge Genomics is a biotechnology company focused on transforming drug discovery through the application of artificial intelligence. Founded by experts in machine learning and seasoned neuroscience drug developers, the company aims to leverage advancements in computational genomics and insights into neuroscience to discover innovative therapeutics for neurodegenerative diseases. Its drug discovery platform employs machine learning algorithms to analyze large datasets, identifying potential drug targets and predicting effective treatments. By accelerating the development of life-saving therapies, Verge Genomics seeks to enhance patient outcomes and reduce the costs associated with pharmaceutical development, thereby addressing critical challenges in the healthcare sector.

Lucira Health, Inc. is a medical technology company that specializes in the development and commercialization of innovative infectious disease test kits. Founded in 2013 and based in Emeryville, California, Lucira has created a consumer-friendly, single-use testing platform that delivers centralized-laboratory-accurate molecular testing. Their flagship product is a disposable COVID-19 test kit that can be used at home, featuring a mobile application that connects users to treatment options. The kit is powered by two AA batteries and is compact enough to fit in the palm of a hand. Additionally, Lucira has developed a 2-in-1 lab testing solution that can determine if viral respiratory symptoms are due to COVID-19 or the flu, enhancing the accessibility and convenience of viral testing for consumers.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

Atomwise, Inc. is a biotechnology company specializing in deep learning artificial intelligence technology for small molecule drug discovery. Based in San Francisco and founded in 2012, the company has developed AtomNet, a pioneering AI platform that facilitates virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical analysis of experimental affinity measurements and protein structures. Atomwise is focused on addressing over 600 unique disease targets and has established collaborations with over 250 partners, including prominent pharmaceutical and biotechnology firms. By leveraging its advanced technology, Atomwise aims to revolutionize the drug discovery process and advance a pipeline of small-molecule drug candidates into preclinical studies. The company was previously known as Chematria, Inc. and rebranded to Atomwise, Inc. in 2015.

Emerald Cloud Lab, Inc. is a biotechnology company based in South San Francisco, California, established in 2010 by two scientists. It provides a fully automated life sciences laboratory designed to enhance the efficiency and effectiveness of scientific research. The Emerald Cloud Laboratory supports a variety of experimental types by managing all aspects of daily lab operations, including method design, sample preparation, data acquisition, and analysis. This comprehensive workspace allows scientists to focus on the more critical aspects of their work, such as designing protocols and analyzing data, rather than getting bogged down by routine tasks. By emphasizing innovation in laboratory processes and tools, Emerald aims to accelerate advancements in life sciences research, emulating the rapid technological progress seen in the semiconductor industry.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

Tempo Automation Holdings, established in 2013 and headquartered in San Francisco, specializes in manufacturing low-volume electronics products. The company's core business involves designing and assembling printed circuit boards (PCBs) using a unique, software-automated platform. This platform enables Tempo to provide unparalleled speed, quality, and transparency, particularly during the critical prototype and new product introduction stages. Serving leading innovators across industries such as aerospace, medical technology, and automotive, Tempo Automation empowers its customers to accelerate product development and time to market.

Eat Just, Inc., founded in 2011 and based in San Francisco, California, focuses on creating plant-based food products aimed at improving the food system. The company offers a variety of items, including plant-based scrambled eggs, flavored mayonnaise, dressings, cookie doughs, and meat alternatives. Their flagship product, JUST Egg, has garnered significant recognition, being featured in lists such as Popular Science's "100 Greatest Innovations." Eat Just emphasizes innovation through a unique discovery platform for food ingredients, combining scientific research with culinary expertise from Michelin-starred chefs. The company has been acknowledged in various prestigious lists, including Fast Company’s "Most Innovative Companies" and Entrepreneur’s "100 Brilliant Companies."

Plethora Corporation is a precision machining company that specializes in CNC machining, milling, and turning of various materials, including aluminum alloys, copper alloys, plastics, steels, and stainless steels. Founded in 2012 and headquartered in San Francisco, California, with an additional office in Marietta, Georgia, Plethora serves a diverse range of industries, such as robotics, automotive, aerospace, and consumer packaged goods, in the United States. The company offers innovative manufacturing systems that transform customer designs into custom parts by utilizing robotics and proprietary in-house software. Plethora also provides design feedback by analyzing CAD models directly within the client's CAD software, ensuring optimized manufacturing processes.

Miroculus, Inc. is a biotechnology company specializing in non-invasive molecular data gathering and analysis solutions. Founded in 2014 and based in San Francisco, California, Miroculus develops advanced digital microfluidic technology that automates and miniaturizes genomic protocols, such as next-generation sequencing library preparation, cell editing, and synthetic biology. The company's hands-off sample-to-answer platform provides assay flexibility and integrates seamlessly into existing workflows, enabling the detection and monitoring of diseases at the molecular level. Miroculus serves a wide range of clients, including academic institutions, genomic research centers, pharmaceuticals, biotechnology firms, and diagnostic companies, offering low-cost, accurate, and minimally invasive molecular testing tools with its proprietary cartridge-based system.

uBiome, Inc. was a microbial genomics company based in San Francisco, California, founded in 2012. It specialized in sequencing-based clinical microbiome tests, offering products such as SmartGut, a test for identifying pathogenic and commensal microorganisms related to infections, and SmartJane, a women's health screening test that detects various conditions including HPV and STIs. The company also provided Explorer kits for citizen scientists and researchers, as well as SmartFlu, a clinical respiratory test. By leveraging precision sequencing combined with machine learning and artificial intelligence, uBiome aimed to enhance the understanding of the human microbiome, enabling healthcare providers to deliver more accurate diagnoses and empowering patients to manage their health more effectively. However, uBiome faced financial difficulties and filed for Chapter 11 bankruptcy in September 2019, which was later converted to Chapter 7 on October 11, 2019.

uBiome, Inc. was a microbial genomics company based in San Francisco, California, founded in 2012. It specialized in sequencing-based clinical microbiome tests, offering products such as SmartGut, a test for identifying pathogenic and commensal microorganisms related to infections, and SmartJane, a women's health screening test that detects various conditions including HPV and STIs. The company also provided Explorer kits for citizen scientists and researchers, as well as SmartFlu, a clinical respiratory test. By leveraging precision sequencing combined with machine learning and artificial intelligence, uBiome aimed to enhance the understanding of the human microbiome, enabling healthcare providers to deliver more accurate diagnoses and empowering patients to manage their health more effectively. However, uBiome faced financial difficulties and filed for Chapter 11 bankruptcy in September 2019, which was later converted to Chapter 7 on October 11, 2019.

Vicarious is an artificial intelligence company that utilizes the principles of neuro and cognitive science to create general intelligence for robots. Founded in 2010 by Dr. Dileep George and D. Scott Phoenix, Vicarious develops technology that mimics the functions of the human brain, aiming to achieve human-level intelligence in areas such as vision, language, and motor control. The company's algorithmic architecture focuses on visual perception challenges, including recognition, segmentation, and scene parsing. This innovative approach enables robot manufacturers to design robots that exhibit advanced intelligence and enhanced task efficiency, positioning Vicarious as a leader in the advancement of intelligent robotic systems.

Human Longevity (HLI) is a genomic-based health intelligence company focused on proactive healthcare and enhancing quality of life. Founded in 2013 and headquartered in San Diego, California, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with advanced machine learning techniques, to drive medical discoveries and transform healthcare practices. The company operates multiple business areas, including the HLI Health Nucleus, a clinical research center that employs whole-genome sequencing, advanced imaging, and curated personal health data to provide an in-depth understanding of individual health. HLI's platform also addresses age-related decline in stem cell function and focuses on major health issues such as cancer, diabetes, obesity, heart and liver diseases, and dementia. By integrating DNA sequencing with expert analysis, HLI aims to empower individuals to take control of their health and shift medical care from a reactive to a proactive approach.

Cleversafe, Inc. is a developer of innovative web-scale storage solutions based in Chicago, Illinois. Founded in 2004, the company specializes in enterprise storage systems that enable businesses to store, manage, and access data at petabyte scale and beyond. Cleversafe's offerings include content repository, Storage-as-a-Service, enterprise collaboration, backup, and archiving solutions, catering to a diverse array of industries such as financial services, healthcare, media, oil and gas, and government sectors. The company is particularly known for its dispersed storage technology, which allows for the deployment of dispersed storage networks, providing organizations with scalable and economically efficient data storage options. Cleversafe's solutions address the challenges posed by the exponential growth of unstructured data, ensuring effective management and security while simplifying application deployment and scalability. As of November 2015, Cleversafe operates as a subsidiary of International Business Machines Corporation.

LightSail Energy focuses on the development of advanced energy storage systems that utilize compressed air technology. The company aims to modernize the electrical grid globally by providing efficient, grid-scale energy storage solutions. These systems are designed to enhance the reliability of renewable energy sources, such as solar and wind, allowing for on-demand energy delivery. By shifting its emphasis from vehicle-based technologies to large-scale applications, LightSail Energy offers clients cost-effective options for energy storage, contributing to a more sustainable energy landscape.